Type 2 diabetes
Type II diabetes is also called adult-onset diabetes. It usually develops after the age of 35 to 40 and accounts for more than 90% of diabetes patients. The ability to produce insulin in patients with type 2 diabetes is not completely lost. Some patients even produce too much insulin, but the effect of insulin is greatly reduced. Therefore, the insulin in the patient's body is relatively deficient. Certain oral medications can be used to stimulate the secretion of insulin in the body. However, in the later stages, some patients still need insulin treatment like type 1 diabetes.
-
Site of disease:
whole body -
Infectious :
Not contagious -
Frequent population:
Middle-aged and elderly people -
Related symptoms:
Polyuria Polydipsia Fatigue Increased blood sugar level Weight loss -
Concurrent disease:
Related Drugs
Glipizide Extended Release Tablets
Indication: It is suitable for patients with mild to moderate type 2 diabetes who have not achieved satisfactory results with diet control and physical exercise for 2 to 3 months. The pancreatic beta cells of such diabetic patients must have a certain insulin secretion function, and have no acute complications (such as infection trauma, ketoacidosis, hyperosmolar coma, etc.), no pregnancy, and no serious chronic complications.
Manufacturer:
Changzhou Siyao Pharmaceuticals Co., Ltd.
Glipizide Extended Release Tablets
Indication: It is suitable for patients with mild to moderate type 2 diabetes who have not achieved satisfactory results with diet control and physical exercise for 2 to 3 months. The pancreatic beta cells of such diabetic patients must have a certain insulin secretion function, and have no acute complications (such as infection trauma, ketoacidosis, hyperosmolar coma, etc.), no pregnancy, and no serious chronic complications.
Manufacturer:
Changzhou Siyao Pharmaceuticals Co., Ltd.
Glipizide Extended Release Tablets
Indication: It is suitable for patients with mild to moderate type 2 diabetes who have not achieved satisfactory results with diet control and physical exercise for 2 to 3 months. The pancreatic beta cells of such diabetic patients must have a certain insulin secretion function, and have no acute complications (such as infection trauma, ketoacidosis, hyperosmolar coma, etc.), no pregnancy, and no serious chronic complications.
Glipizide Extended Release Tablets
Indication: It is suitable for patients with mild to moderate type 2 diabetes who have not achieved satisfactory results with diet control and physical exercise for 2 to 3 months. The pancreatic beta cells of such diabetic patients must have a certain insulin secretion function, and have no acute complications (such as infection, trauma, ketoacidosis, hyperosmolar coma, etc.), no pregnancy, and no serious chronic complications.
Glipizide Tablets
Indication: It is suitable for patients with mild to moderate type 2 diabetes who have not achieved satisfactory results with diet control and physical exercise for 2 to 3 months. The pancreatic islet cells of such diabetic patients must have a certain insulin secretion function, and have no acute complications (such as infection, trauma, ketoacidosis, hyperosmolar coma, etc.), no pregnancy, and no serious chronic complications.
Glipizide Tablets
Indication: It is suitable for patients with mild to moderate type 2 diabetes who have not achieved satisfactory results after 2 to 3 months of diet control and physical exercise. The pancreatic islet b cells of such diabetic patients must have a certain insulin secretion function, and have no acute complications (such as infection, trauma, ketoacidosis, hyperosmolar coma, etc.), no pregnancy, and no serious chronic complications.
Glipizide Tablets
Indication: It is suitable for patients with mild to moderate type 2 diabetes who have not achieved satisfactory results after 2 to 3 months of diet control and physical exercise. The pancreatic islet b cells of such diabetic patients must have a certain insulin secretion function, and have no acute complications (such as infection, trauma, ketoacidosis, hyperosmolar coma, etc.), no pregnancy, and no serious chronic complications.
Glipizide Tablets
Indication: It is suitable for patients with mild to moderate type 2 diabetes who have not achieved satisfactory results after 2 to 3 months of diet control and physical exercise. The pancreatic islet b cells of such diabetic patients must have a certain insulin secretion function, and have no acute complications (such as infection, trauma, ketoacidosis, hyperosmolar coma, etc.), no pregnancy, and no serious chronic complications.
Manufacturer:
Tianjin Zhongtian Pharmaceutical Co., Ltd.
Nateglinide capsules
Indication: This product can be used alone for patients with type 2 diabetes who cannot effectively control hyperglycemia through diet and exercise. It can also be used in combination with metformin for patients with type 2 diabetes who cannot effectively control hyperglycemia, but it cannot replace metformin. Nateglinide is not suitable for patients with type 2 diabetes who are not ideal for sulfonylurea hypoglycemic treatment.
Manufacturer:
Shi Huida Pharmaceutical Group (Jilin) Co., Ltd.
Naglina
Indication: This product can be used alone for patients with type 2 diabetes who cannot effectively control hyperglycemia through diet and exercise, or for patients with type 2 diabetes who cannot effectively control hyperglycemia with metformin. It is used in combination with metformin, but it cannot replace metformin. Nateglinide is not suitable for patients with type 2 diabetes who are not ideal for treatment with sulfonylurea hypoglycemic drugs.
Manufacturer:
Lianyungang Runzhong Pharmaceutical Co., Ltd.